Novel methods and devices to enhance transdermal drug delivery: The importance of laser radiation in transdermal drug delivery

Therapeutic Delivery

Volumn 3, Issue 3, 2012, Pages 373-388

  Gómez, Clara ^a   Benito, Marta ^b   Teijón, José Maria ^c   Blanco, Maria Dolores ^c  

^a INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^b UNIVERSIDAD ANTONIO DE NEBRIJA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOLEVULINIC ACID; ANGIOTENSIN; APOMORPHINE; CALCITONIN; CHROMIUM; DICLOFENAC; DNA VACCINE; FENTANYL; FENTANYL CITRATE; FERTILITY PROMOTING AGENT; FLUOROURACIL; GALLIUM; HUMAN GROWTH HORMONE; INFLUENZA VACCINE; INSULIN; KETOPROFEN; LIDOCAINE; LIPOSOME; METHOTREXATE; NANOPARTICLE; OXYCODONE; PARATHYROID HORMONE[1-34]; RETINOIC ACID; SCANDIUM; TESTOSTERONE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VACCINE; YTTRIUM;

CARBON DIOXIDE LASER; CHEMICAL MODIFICATION; DEVICE SAFETY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; ELECTROPORATION; EQUIPMENT DESIGN; ERBIUM YAG LASER; HUMAN; HYDROPHILICITY; IONTOPHORESIS; JET INJECTION; JET INJECTOR; LASER; LIPOSOMAL DELIVERY; MACROMOLECULE; MICRODERMABRASION; MICROINJECTOR; NANOENCAPSULATION; NANOPHARMACEUTICS; NEEDLE; NONHUMAN; PORTABLE EQUIPMENT; PRIORITY JOURNAL; REVIEW; SKIN CARE; SKIN PERMEABILITY; STRATUM CORNEUM; ULTRASOUND;

EID: 84858136164     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.10     Document Type: Review

References (82)

1. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. Technol. Today 3(9), 318-326 (2000).
2. Coderch L, Fonollosa J, De Pera M, Estelrich J, De La Maza A, Parra JL. Influence of cholesterol on liposome fluidity by EPR. Relationship with percutaneous absorption. J. Control. Release 68(1), 85-95 (2000). (Pubitemid 30407064)
3. Rai K, Gupta Y, Jain A, Jain SK. Transfersomes: self-optimizing carriers for bioactives. PDA J. Pharm. Sci. Technol. 62(5), 362-379 (2008).
4. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biol. Pharm. Bull. 34(7), 945-953 (2011).
5. Ainbinder D, Paolino D, Fresta M, Touitou E. Drug delivery applications with ethosomes. J. Biomed. Nanotechnol. 6(5), 558-568 (2010).
6. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Release 123(2), 148-154 (2007). (Pubitemid 47562141)
7. Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur. J. Pharm. Biopharm. 73(3), 391-398 (2009).
8. Sinico C, Fadda AM. Vesicular carriers for dermal drug delivery. Expert Opin. Drug Deliv. 6(8), 813-825 (2009).
9. Gupta M, Tiwari S, Vyas SP. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm. Dev. Technol. (2011) (Epub ahead of print).
10. Kim ST, Jang DJ, Kim JH et al. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie 64(8), 510-514 (2009).
11. Cirri M, Bragagni M, Mennini N, Mura P. Development of a new delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for ketoprofen topical delivery. Eur. J. Pharm. Biopharm. 80(1), 46-53 (2012).
12. Puglia C, Sarpietro MG, Bonina F, Castelli F, Zammataro M, Chiechio S. Development, characterization, and In vitro and in vivo evaluation of benzocaine-and lidocaine-loaded nanostructrured lipid carriers. J. Pharm. Sci. 100(5), 1892-1899 (2011).
13. Gonzalez-Mira E, Nikolic S, Garcia ML, Egea MA, Souto EB, Calpena AC. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J. Pharm. Sci. 100(1), 242-251 (2011).
14. Abdel-Mottaleb MM, Neumann D, Lamprecht A. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur. J. Pharm. Biopharm. 79(1), 36-42 (2011).
15. Alves MP, Scarrone AL, Santos M, Pohlmann AR, Guterres SS. Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int. J. Pharm. 341(1-2), 215-220 (2007). (Pubitemid 47088101)
16. Mak WC, Richter H, Patzelt A et al. Drug delivery into the skin by degradable particles. Eur. J. Pharm. Biopharm. 79(1), 23-27 (2011).
17. Arora A, Hakim I, Baxter J et al. Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc. Natl Acad. Sci. USA 104(11), 4255-4260 (2007). (Pubitemid 47186213)
18. Stachowiak JC, Li TH, Arora A, Mitragotri S, Fletcher DA. Dynamic control of needle-free jet injection. J. Control. Release 135(2), 104-112 (2009).
19. Bauer D, Lu M, Wasmuth S et al. Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense. Graefes Arch. Clin. Exp. Ophthalmol. 244(2), 216-225 (2006).
20. Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008).
21. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop. J. Pharm. Res. 8(2), 173-179 (2009).
22. Furuishi T, Oda S, Saito H, Fukami T, Suzuki T, Tomono K. Effect of permeation enhancers on the in vitro percutaneous absorption of pentazocine. Biol. Pharm. Bull. 30(7), 1350-1353 (2007). (Pubitemid 47037660)
23. Kanikkannan N, Bahu RJ, Singh M. Structure-activity relationship of chemical penetration enhancers. In: Percutaneous Penetration Enhancers (2nd Edition). Smith EW, Maibach HI (Eds). CRC Press, Boca Raton, FL, USA, 17-34 (2006).
24. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc. Natl Acad. Sci. USA 102(13), 4688-4693 (2005). (Pubitemid 40471515)
25. Karande P, Mitragotri S. Enhancement of transdermal drug delivery via synesgistic action of chemicals. Biochim. Biophys. Acta 1788, 2362-2373 (2009).
26. Lavon I, Grossman N, Kost J, Kimmel E, Enden G. Bubble growth within the skin by rectified diffusion might play a significant role in sonophoresis. J. Control. Release 117(2), 246-255 (2007). (Pubitemid 46172501)
27. Sarheed O, Abdul Rasool BK. Development of an optimised application protocol for sonophoretic transdermal delivery of a model hydrophilic drug. Open Biomed. Eng. J. 5, 14-24 (2011).
28. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J. Control. Release 152(3), 330-348 (2011).
29. Park D, Yoon J, Park J, Jung B, Park H, Seo J. Transdermal drug delivery aided by an ultrasound contrast agent: an in vitro experimental study. Open Biomed. Eng. J. 4, 56-62 (2010).
30. Park EJ, Werner J, Smith NB. Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm. Res. 24(7), 1396-1401 (2007). (Pubitemid 46870602)
31. Kim TY, Jung DI, Kim YI, Yang JH, Shin SC. Anesthetic effects of lidocaine hydrochloride gel using low frequency ultrasound of 0.5 MHz. J. Pharm. Pharm. Sci. 10(1), 1-8 (2007).
32. Maruani A, Boucaud A, Perrodeau E, Gendre D, Giraudeau B, Machet L. Low-frequency ultrasound sonophoresis to increase the efficiency of topical steroids: a pilot randomized study of humans. Int. J. Pharm. 395(1-2), 84-90 (2010).
33. Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency ultrasound as a transcutaneous inmunization adjuvant. Vaccine 23(29), 3800-3807 (2005). (Pubitemid 40704743)
34. Paliwal S, Menon GK, Mitragotri S. Low-frequency sonophoresis: ultrastructural basis for stratum corneum permeability assessed using quantum dots. J. Invest. Dermatol. 126(5), 1095-1101 (2006).
35. Kasha PC, Banga AK. A review of patent literature for iontophoretic delivery and devices. Recent Pat. Drug Deliv. Formul. 2(1), 41-50 (2008). (Pubitemid 351546433)
36. Dixit N, Bali V, Baboota S, Ahuja A, Ali J. Iontophoresis-an approach for controlled drug delivery: a review. Curr. Drug Deliv. 4(1), 1-10 (2007). (Pubitemid 46066409)
37. Swain S, Beg S, Singh A, Patro ChN, Rao ME. Advanced techniques for penetration enhancement in transdermal drug delivery system. Curr. Drug Deliv. 8(4), 456-473 (2011).
38. Subramony JA, Sharma A, Phipps JB. Microprocessor controlled transdermal drug delivery. Int. J. Pharm. 317(1), 1-6 (2006). (Pubitemid 43866349)
39. Gratieri T, Kalaria D, Kalia YN. Non-invasive iontophoretic delivery of peptides and proteins across the skin. Expert Opin. Drug Deliv. 8(5), 645-663 (2011).
40. Xu Q, Ibrahim SA, Higuchi WI, Li SK. Ion-exchange membrane assisted transdermal iontophoretic delivery of salicylate and acyclovir. Int. J. Pharm. 369(1-2), 105-113 (2009).
41. Takmaz EA, Inal O, Baykara T. Studies on transdermal delivery enhancement of zidovudine. AAPS Pharm. Sci. Tech. 10(1), 88-97 (2009).
42. Kigasawa K, Kajimoto K, Nakamura T et al. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy. J. Control. Release 150(3), 256-265 (2011).
43. Hikima T, Ohsumi S, Shirouzu K, Tojo K. Mechanisms of synergistic skin penetration by sonophoresis and iontophoresis. Biol. Pharm. Bull. 32(5), 905-909 (2009).
44. Nolan LM, Corish J, Corrigan OI, Fitzpatrick D. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin. Int. J. Pharm. 341(1-2), 114-124 (2007). (Pubitemid 47088117)
45. Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J. Pharm. Pharmacol. 60(1), 27-33 (2008).
46. Li S. Electroporation Protocols: Preclinical and Clinical Gene Medicine. Humana Press, NY, USA (2008).
47. Wong TW, Chen TY, Huang CC, Tsai JC, Hui SW. Painless skin electroporation as a novel way for insulin delivery. Diabetes Technol. Ther. 13(9), 929-935 (2011).
48. Liu HZ, Wang YJ, Xu L, Li SM. Investigation into the potential of electroporation facilitated topical delivery of cyclosporin a. PDA J. Pharm. Sci. Technol. 64(3), 191-199 (2010).
49. Lin F, Shen X, McCoy JR et al. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29(39), 6771-6780 (2011).
50. Tokumoto S, Higo N, Sugibayashi K. Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin. Int. J. Pharm. 326(1-2), 13-19 (2006). (Pubitemid 44647740)
51. Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opin. Drug Deliv. 7(5), 617-629 (2010).
52. Prausnitz MR, Gill HS, Park JH. Micronnedles for drug delivery. In: Modified-Release Drug Delivery Technology (2nd Edition). Rathbone MJ, Hadgraft J, Roberts MS, Lane ME (Eds). Informa Healthcare, NY, USA, 295-309 (2008).
53. Wonglertnirant N, Todo H, Opanasopit P, Ngawhirunpat T, Sugibayashi K. Macromolecular delivery into skin using a hollow microneedle. Biol. Pharm. Bull. 33(12), 1988-1993 (2010).
54. Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm. Res. 28(5), 1211-1219 (2011).
55. Park JH, Choi SO, Seo S, Choy YB, Prausnitz MR. A microneedle roller for transdermal drug delivery. Eur. J. Pharm. Biopharm. 76(2), 282-289 (2010).
56. Chu LY, Prausnitz MR. Separable arrowhead microneedles. J. Control. Release 149(3), 242-249 (2011).
57. Ito Y, Murakami A, Maeda T, Sugioka N, Takada K. Evaluation of self-dissolving needles containing low molecular weight heparin (LMWH) in rats. Int. J. Pharm. 349(1-2), 124-129 (2008). (Pubitemid 350299697)
58. Burton SA, Ng CY, Simmers R et al. Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm. Res. 28(1), 31-40 (2011).
59. Andrews S, Lee JW, Choi SO, Prausnitz MR. Transdermal insulin delivery using microdermabrasion. Pharm. Res. 28(9), 2110-2118 (2011).
60. Lee WR, Tsai RY, Fang CL, Liu CJ, Hu CH, Fang JY. Microdermabrasion as a novel tool to enhance drug delivery via the skin: an animal study. Dermatol. Surg. 32(8), 1013-1022 (2006).
61. Gill HS, Andrews SN, Sakthivel SK et al. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur. J. Pharm. Sci. 38(2), 95-103 (2009).
62. Andrews SN, Zarnitsyn V, Bondy B, Prausnitz MR. Optimization of microdermabrasion for controlled removal of stratum corneum. Int. J. Pharm. 407(1-2), 95-104 (2011).
63. Dudelzak J, Hussain M, Phelps RG, Gottlieb GJ, Goldberg DJ. Evaluation of histologic and electron microscopic changes after novel treatment using combined microdermabrasion and ultrasound-induced phonophoresis of human skin. J. Cosmet Laser Ther. 10(4), 187-192 (2008).
64. Gomez C, Costela A, Garcia-Moreno I, Llanes F, Teijon JM, Blanco MD. Skin laser treatments enhancing transdermal delivery of ALA. J. Pharm. Sci. 100(1), 223-231 (2011).
65. Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study. J. Control. Release 115(3), 344-353 (2006).
66. Lee WR, Pan TL, Wang PW, Zhuo RZ, Huang CM, Fang JY. Erbium:YAG laser enhances transdermal peptide delivery and skin vaccination. J. Control. Release 128(3), 200-208 (2008).
67. Lee WR, Shen SC, Fang CL, Zhuo RZ, Fang JY. Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: low-fluence erbium:YAG laser and electroporation. Lasers Surg. Med. 40(7), 468-476 (2008).
68. Hohenleutner U, Hohenleutner S, Baumler W, Landthaler M. Fast and effective skin ablation with an Er:YAG laser: determination of ablation rates and thermal damage zones. Lasers Surg. Med. 20(3), 242-247 (1997). (Pubitemid 27200201)
69. Lee WR, Shen SC, Wang KH, Hu CH, Fang JY. The effect of laser treatment on skin to enhance and control transdermal delivery of 5-fluorouracil. J. Pharm. Sci. 91(7), 1613-1626 (2002).
70. Hsiao CY, Huang CH, Hu S, Ko YS, Sung HC, Huang SY. Skin pretreatment with lasers promotes the transdermal delivery of vitamin C derivatives. Lasers Med. Sci. 26(3), 369-376 (2011).
71. DiBernardo B. Assessment of the impact of high-fluence, high-overlap settings on full face treatments with the 2,790 nm Pearl YSGG laser. Lasers Surg. Med. 40, 34 (2008).
72. Geraghty LN, Biesman B. Clinical evaluation of a single-wavelength fractional laser and a novel multi-wavelength fractional laser in the treatment of photodamaged skin. Lasers Surg. Med. 41(6), 408-416 (2009).
73. Geronemus RG. Fractional photothermolysis: current and future applications. Lasers Surg. Med. 38(3), 169-176 (2006).
74. Hantash BM, Bedi VP, Kapadia B et al. In vivo histological evaluation of a novel ablative fractional resurfacing device. Lasers Surg. Med. 39(2), 96-107 (2007). (Pubitemid 46411402)
75. Lee WR, Shen SC, Pai MH, Yang HH, Yuan CY, Fang JY. Fractional laser as a tool to enhance the skin permeation of 5-aminolevulinic acid with minimal skin disruption: a comparison with conventional erbium:YAG laser. J. Control. Release 145(2), 124-133 (2010).
76. Lee WR, Shen SC, Al-Suwayeh SA, Yang HH, Yuan CY, Fang JY. Laser-assisted topical drug delivery by using a low-fluence fractional laser: imiquimod and macromolecules. J. Control. Release 153(3), 240-248 (2011).
77. Haedersdal M, Sakamoto FH, Farinelli WA, Doukas AG, Tam J, Anderson RR. Fractional CO(2) laser-assisted drug delivery. Lasers Surg. Med. 42(2), 113-122 (2010).
78. Yoo KH, Kim BJ, Kim MN. Enhanced efficacy of photodynamic therapy with methyl 5-aminolevulinic acid in recalcitrant periungual warts after ablative carbon dioxide fractional laser: a pilot study. Dermatol. Surg. 35(12), 1927-1932 (2009).
79. Koh JL, Harrison D, Swanson V, Norvell DC, Coomber DC. A comparison of aser-assisted drug delivery at two output energies for enhancing the delivery of topically applied LMX-4 cream prior to venipuncture. Anesth. Analg. 104(4), 847-849 (2007). (Pubitemid 46548307)
80. Yu J, Kalaria DR, Kalia YN. Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. J. Control. Release 156(1), 53-59 (2011).
81. Bachhav YG, Summer S, Heinrich A, Bragagna T, Bohler C, Kalia YN. Effect of controlled laser microporation on drug transport kinetics into and across the skin. J. Control. Release 146(1), 31-36 (2010).
82. Bachhav YG, Heinrich A, Kalia YN. Using laser microporation to improve transdermal delivery of diclofenac: increasing bioavailability and the range of therapeutic applications. Eur. J. Pharm. Biopharm. 78(3), 408-414 (2011).